Interleukin-17, a salivary biomarker for COVID-19 severity.

Autor: Sharif-Askari FS; Sharjah Institute of Medical Research, University of Sharjah, Sharjah, United Arab Emirates., Sharif-Askari NS; Sharjah Institute of Medical Research, University of Sharjah, Sharjah, United Arab Emirates., Hafezi S; Sharjah Institute of Medical Research, University of Sharjah, Sharjah, United Arab Emirates., Mdkhana B; Sharjah Institute of Medical Research, University of Sharjah, Sharjah, United Arab Emirates., Alsayed HAH; Pharmacy Department, Dubai Health Authority, Dubai, United Arab Emirates., Ansari AW; Dermatology Institute, Translational Research Institute, Hamad Medical Corporation, Doha, Qatar., Mahboub B; Rashid Hospital, Dubai Health Authority, Dubai, United Arab Emirates., Zakeri AM; Department of Plant Production, Faculty of Agriculture and Food Sciences, King Saud University, Riyadh, Saudi Arabia., Temsah MH; Department of Pediatrics, Immunology Research Lab, College of Medicine, King Saud University, Riyadh, Saudi Arabia., Zahir W; G42 Health Care, Abu Dhabi, United Arab Emirates.; Institute of Public Health, United Arab Emirates University, Al Ain, United Arab Emirates., Hamid Q; Sharjah Institute of Medical Research, University of Sharjah, Sharjah, United Arab Emirates.; Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates.; Meakins-Christie Laboratories, Research Institute of the McGill University Health Center, Montreal, Quebec, Canada., Halwani R; Sharjah Institute of Medical Research, University of Sharjah, Sharjah, United Arab Emirates.; Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates.; Prince Abdullah Ben Khaled Celiac Disease Chair, Department of Pediatrics, Faculty of Medicine, King Saud University, Riyadh, Saudi Arabia.
Jazyk: angličtina
Zdroj: PloS one [PLoS One] 2022 Sep 22; Vol. 17 (9), pp. e0274841. Date of Electronic Publication: 2022 Sep 22 (Print Publication: 2022).
DOI: 10.1371/journal.pone.0274841
Abstrakt: Objectives: T-helper 17 cell-mediated response and their effector IL-17 cytokine induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is a major cause of COVID-19 disease severity and death. Therefore, the study aimed to determine if IL-17 level in saliva mirrors its circulatory level and hence can be used as a non-invasive biomarker for disease severity.
Methods: Interleukin-17 (IL-17) level was evaluated by ELISA in saliva and blood of 201 adult COVID-19 patients with different levels of severity. The IL-17 saliva level was also associated with COVID-19 disease severity, and need for mechanical ventilation and/or death within 29 days after admission of severe COVID-19 patients.
Results: We found that IL-17 level in saliva of COVID-19 patients reflected its circulatory level. High IL-17 level in saliva was associated with COVID-19 severity (P<0.001), need for mechanical ventilation (P = 0.002), and/or death by 29 days (P = 0.002), after adjusting for patients' demographics, comorbidity, and COVID-19 serum severity markers such as D-Dimer, C-reactive protein, and ferritin.
Conclusion: We propose that saliva IL-17 level could be used as a biomarker to identify patients at risk of developing severe COVID-19.
Competing Interests: The authors have declared that no competing interests exist.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje